- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2015 (adults) and 2023 (pediatric).
- Why 3/10
- Cresemba is already approved and marketed with no pending regulatory decision or pivotal readout in the next 12 months. It is a small product within Pfizer's massive portfolio, so even a major sales milestone is immaterial to PFE's share price.
Cresemba is a mature, approved product with no upcoming binary catalysts. The key event to watch is the next quarterly sales milestone from Pfizer to Basilea, which would signal continued commercial momentum, but this is immaterial to Pfizer's stock. For Basilea (SIX: BSLN), Cresemba royalty and milestone income is the primary value driver.
Price Chart
Executive Summary
Cresemba (isavuconazonium sulfate / isavuconazole) is an approved azole antifungal for invasive aspergillosis and mucormycosis, first FDA-approved in March 2015 with pediatric expansion in December 2023. Pfizer holds exclusive commercialization rights in Europe, China, and Asia Pacific under a license from Basilea Pharmaceutica, paying Basilea milestone payments and mid-teen royalties. Global in-market sales reached $817M over the 12 months through June 2026 (up 25% YoY), making it the world's largest branded antifungal. However, for Pfizer (PFE), a $62.6B revenue company, Cresemba is a small, non-core product not among its top 10 revenue drivers, with no upcoming binary catalysts. The drug is most consequential for Basilea (SIX: BSLN), for whom it is the primary revenue generator.
How It Works
Cresemba is an antifungal medication (a triazole) that works by blocking the production of ergosterol, a key component of fungal cell membranes. Without ergosterol, the fungal cell membrane becomes unstable and the fungus dies. It is given as a prodrug (isavuconazonium sulfate) that converts to the active drug isavuconazole in the bloodstream. It is available in both intravenous (IV) and oral capsule forms, allowing patients to switch from hospital treatment to home therapy.
Trial Status
Cresemba is fully approved by the FDA (March 2015 for adults, expanded December 2023 for children aged 1+), EMA (October 2015), and other global regulators. It is commercially marketed in more than 70 countries by Pfizer (Europe, Asia Pacific, China) and Astellas (US). No pivotal clinical trials are ongoing for new indications.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates or pivotal readouts for Cresemba. The next catalyst would be periodic sales milestone announcements from Basilea when Pfizer's cumulative sales cross contractual thresholds, but these are not dated events and are immaterial to Pfizer's stock.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report